Background: Antibodies to M-type phospholipase A2 receptor (PLA2R) correlate with clinical activity of primary membranous nephropathy (PMN). Risk alleles in PLA2R1 and HLA-DQA1 genes are associated with PMN. Whether these alleles are associated with the development of anti-PLA2R is unknown. In this prospective study we evaluated anti-PLA2R, enhanced glomerular staining for PLA2R and variations in PLA2R1 and HLA-DQA1 genes in Indian patients with PMN and examined their association with response to treatment.
Methods: A total of 114 adult PMN patients were studied. Anti-PLA2R was estimated before treatment and after 6 and 12 months of therapy. Enhanced glomerular staining for PLA2R was assessed on fresh frozen tissue. Genotype analysis was done on recruited patients and 95 healthy controls by TaqMan assays for six single-nucleotide polymorphisms (SNPs; rs4664308, rs3749119, rs3749117, rs4664308, rs3828323 and rs2187668). Patients were followed up monthly for a period of 12 months.
Results: Of 114 patients, 66.7% showed elevated serum anti-PLA2R by ELISA and 64.9% by indirect immunofluorescence. About 75% had enhanced glomerular staining for PLA2R. A total of 82% of patients had PLA2R-related disease. Reduction in serum anti-PLA2R titer had a significant association with remission of nephrotic syndrome (P = 0.0003) at 6 and 12 months. More than 85% of patients showing >90% reduction in the anti-PLA2R titer achieved remission of the nephrotic state, whereas of those showing <50% reduction in titers, 87.5% had persistent nephrotic state. The SNPs rs3749119, rs3749117, rs4664308 in PLA2R1 and rs2187668 in HLA-DQA1 were significantly associated with PMN. The SNP rs2187668 was associated with anti-PLA2R positivity. Patients with a high-risk genotype had higher anti-PLA2R levels.
Conclusion: To conclude, anti-PLA2R and enhanced glomerular PLA2R staining are found in more than two-thirds of Indian PMN cases. A reduction in the anti-PLA2R titer correlated with response to therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ndt/gfv399 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction: Idiopathic membranous nephropathy (iMN) has become one of the most prevalent primary glomerular diseases, with a marked increase in prevalence over the past two decades in northern China. Fine particulate matter (PM2.5) is considered to be associated with this rising prevalence.
View Article and Find Full Text PDFAssociation of 10 Polymorphisms in PLA2R1 and HLA DQA1 Genes with Primary Membranous Nephropathy Risk: A Meta-Analysis and a Meta-Regression.
Biomark Insights
June 2024
Research Laboratory in Immunology of Renal Transplantation and Immunopathology (LR03SP01), Charles Nicolle Hospital, Tunis El Manar University, Tunis, Tunisia.
Background: Although, several studies have assessed the association of the phospholipase A2 receptor (PLA2R) and HLA-DQA1 SNPs with primary membranous nephropathy (PMN), results were inconsistent and between-studies heterogeneity needs to be investigated.
Objectives: The aim of this review was to summarize existing data on the contribution of 10 SNPs in the PLA2R and HLA-DQA1 genes to PMN susceptibility and to investigate the between-studies heterogeneity by subgroup analyses and meta-regressions.
Design: This study was performed according to the PRISMA guidelines for systematic reviews and meta-analyses.
A Genetic Risk Score Distinguishes Different Types of Autoantibody-Mediated Membranous Nephropathy.
Glomerular Dis
March 2023
UCL Department of Renal Medicine, University College London, London, UK.
Article Synopsis
- Membranous nephropathy (MN) is the main cause of nephrotic syndrome in adults, distinguished by autoantibodies against specific glomerular antigens like PLA2R1 and THSD7A.
- Researchers genotyped 1,409 MN patients to compare genetic risk factors associated with different autoantibody statuses against a control group.
- The findings show that patients with anti-PLA2R1 antibodies have a higher genetic risk score (GRS) compared to controls and those with anti-THSD7A antibodies, indicating distinct genetic influences and suggesting some antibody-negative MN cases might still be linked to autoimmunity against PLA2R1.
Peptide GAM immunoadsorption in anti-PLA R positive autoimmune membranous nephropathy. The PRISM trial.
J Clin Apher
February 2022
Manchester Institute of Nephrology & Transplantation, Manchester Royal Infirmary, Manchester, UK.
Membranous nephropathy associated with anti-PLA R autoantibody is a significant cause of nephrotic syndrome worldwide. Treatment remains empiric with a significant side-effect burden despite an increase in our understanding of the disease. We studied the effect of selectively removing this pathogenic autoantibody using immunoadsorption in adult patients with biopsy proven anti-PLA R membranous nephropathy.
View Article and Find Full Text PDFAssociations between m-type phospholipase A2 receptor,human leukocyte antigen gene polymorphisms and idiopathic membranous nephropathy.
Bioengineered
December 2021
Department of Nephrology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Primary membranous nephropathy, also known as idiopathic membranous nephropathy, is an autoimmune disease. As an autoimmune disease, genetic factors are essential in the pathogenesis of IMN. People pay more and more attention to genetics and bioinformatics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!